Research Summary

I am the Director of Basic Science in the UCSF Brain Tumor Center, the Vice-Chairman of the UCSF Department of Neurological Surgery, and a co-PI of the UCSF Brain Tumor SPORE. I am a recognized expert in the areas of cell signaling, temozolomide-based drug resistance, and gliomagenesis. As the Suzanne Marie Haderle and Robert Vincent Haderle Professor of Molecular Neuro-Oncology, I direct a lab that focuses on genetic events that drive brain tumor formation and drug resistance and that in turn may serve as targets for the development of new therapies for brain tumors.

Research Funding

  • September 20, 2002 - August 31, 2023 - Brain Tumor SPORE Grant, Co-Investigator. Sponsor: NIH/NCI, Sponsor Award ID: P50CA097257
  • September 15, 2017 - May 31, 2022 - Contributions of IDH1 mutation to alternative lengthening of telomeres in lower-grade glioma, Principal Investigator. Sponsor: NIH/NINDS, Sponsor Award ID: R01NS105087
  • September 1, 2010 - August 31, 2020 - Training Program in Translational Brain Tumor Research, Co-Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: T32CA151022
  • February 1, 2013 - January 31, 2018 - Understanding the role of altered metabolism in gliomagenesis, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA171610


University of Wisconsin, Madison, WI, B.S., 1982, Pharmacy
George Washington Univ., Washington, D.C., Ph.D., 1987, Pharmacology

Honors & Awards

  • 2000-present
    Suzanne Marie Haderle and Robert Vincent Haderle Endowed Chair in Molecular Neuro-Oncology

Selected Publications

  1. Radoul M, Hong D, Gillespie AM, Najac C, Viswanath P, Pieper RO, Costello JF, Luchman HA, Ronen SM Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma.  View on PubMed
  2. Viswanath P, Batsios G, Mukherjee J, Gillespie AM, Larson PEZ, Luchman HA, Phillips JJ, Costello JF, Pieper RO, Ronen SM Non-invasive assessment of telomere maintenance mechanisms in brain tumors.  View on PubMed
  3. Subramani E, Radoul M, Najac C, Batsios G, Molloy AR, Hong D, Gillespie AM, Santos RD, Viswanath P, Costello JF, Pieper RO, Ronen SM Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment.  View on PubMed
  4. Ohba S, Murayama K, Kuwahara K, Pareira ES, Nakae S, Nishiyama Y, Adachi K, Yamada S, Sasaki H, Yamamoto N, Abe M, Mukherjee J, Hasegawa M, Pieper RO, Hirose Y The Correlation of Fluorescence of Protoporphyrinogen IX and Status of Isocitrate Dehydrogenase in Gliomas.  View on PubMed
  5. Jones LE, Hilz S, Grimmer MR, Mazor T, Najac C, Mukherjee J, McKinney A, Chow T, Pieper RO, Ronen SM, Chang SM, Phillips JJ, Costello JF Patient-derived cells from recurrent tumors that model the evolution of IDH-mutant glioma.  View on PubMed
  6. Molloy AR, Najac C, Viswanath P, Lakhani A, Subramani E, Batsios G, Radoul M, Gillespie AM, Pieper RO, Ronen SM MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma.  View on PubMed
  7. Ohba S, Johannessen TA, Chatla K, Yang X, Pieper RO, Mukherjee J Phosphoglycerate Mutase 1 Activates DNA Damage Repair via Regulation of WIP1 Activity.  View on PubMed
  8. Batsios G, Viswanath P, Subramani E, Najac C, Gillespie AM, Santos RD, Molloy AR, Pieper RO, Ronen SM PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival.  View on PubMed
  9. Chen D, Xia S, Wang M, Lin R, Li Y, Mao H, Aguiar M, Famulare CA, Shih AH, Brennan CW, Gao X, Pan Y, Liu S, Fan J, Jin L, Song L, Zhou A, Mukherjee J, Pieper RO, Mishra A, Peng J, Arellano M, Blum WG, Lonial S, Boggon TJ, Levine RL, Chen J Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer.  View on PubMed
  10. Radoul M, Najac C, Viswanath P, Mukherjee J, Kelly M, Gillespie AM, Chaumeil MM, Eriksson P, Delos Santos R, Pieper RO, Ronen SM HDAC inhibition in glioblastoma monitored by hyperpolarized 13 C MRSI.  View on PubMed
  11. Wood MD, Mukherjee J, Pieper RO Neurofibromin knockdown in glioma cell lines is associated with changes in cytokine and chemokine secretion in vitro.  View on PubMed
  12. Viswanath P, Radoul M, Izquierdo-Garcia JL, Luchman HA, Gregory Cairncross J, Pieper RO, Phillips JJ, Ronen SM Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner.  View on PubMed
  13. Mukherjee J, Johannessen TC, Ohba S, Chow TT, Jones L, Pandita A, Pieper RO Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma.  View on PubMed
  14. Viswanath P, Radoul M, Izquierdo-Garcia JL, Ong WQ, Luchman HA, Cairncross JG, Huang B, Pieper RO, Phillips JJ, Ronen SM 2-Hydroxyglutarate-Mediated Autophagy of the Endoplasmic Reticulum Leads to an Unusual Downregulation of Phospholipid Biosynthesis in Mutant IDH1 Gliomas.  View on PubMed
  15. Ohba S, Mukherjee J, Johannessen TC, Mancini A, Chow TT, Wood M, Jones L, Mazor T, Marshall RE, Viswanath P, Walsh KM, Perry A, Bell RJ, Phillips JJ, Costello JF, Ronen SM, Pieper RO Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process.  View on PubMed
  16. Hu L, Li X, Liu Q, Xu J, Ge H, Wang Z, Wang H, Wang Z, Shi C, Xu X, Huang J, Lin Z, Pieper RO, Weng C UBE2S, a novel substrate of Akt1, associates with Ku70 and regulates DNA repair and glioblastoma multiforme resistance to chemotherapy.  View on PubMed
  17. Johannessen TA, Mukherjee J, Viswanath P, Ohba S, Ronen SM, Bjerkvig R, Pieper RO Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis.  View on PubMed
  18. Viswanath P, Najac C, Izquierdo-Garcia JL, Pankov A, Hong C, Eriksson P, Costello JF, Pieper RO, Ronen SM Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters.  View on PubMed
  19. Mukherjee J, Ohba S, See WL, Phillips JJ, Molinaro AM, Pieper RO PKM2 uses control of HuR localization to regulate p27 and cell cycle progression in human glioblastoma cells.  View on PubMed
  20. Izquierdo-Garcia JL, Viswanath P, Eriksson P, Cai L, Radoul M, Chaumeil MM, Blough M, Luchman HA, Weiss S, Cairncross JG, Phillips JJ, Pieper RO, Ronen SM IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism.  View on PubMed

Go to UCSF Profiles, powered by CTSI